-
Eli Lilly LLY cuts 2024 income outlook on weight reduction medicine
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images Eli Lilly cut its revenue guidance on Tuesday as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations. The drugmaker’s…
-
Excessive-cost weight reduction medication enhance vitamin counseling with employers
Packages of weight loss drugs Wegovy, Ozempic and Mounjaro. Picture Alliance | Getty Images A few years ago, when Virta Health founder and CEO Sami Inkinen approached employers about leveraging the company’s nutrition-oriented digital diabetes program for obesity-related weight loss, most companies weren’t ready to commit. Now, more employers are all in on nutritional counseling…
-
Surgeon basic points new advisory
A customer drinks a glass of beer at the Saxton Pub in Austin, Texas, April 5, 2023. Brandon Bell | Getty Images The U.S. surgeon general issued a new advisory warning Friday about the link between alcohol consumption and increased cancer risk, and pushed for policy changes to help reduce the number of alcohol-related cancers.…
-
FDA Zepbound scarcity ends, impacts sufferers, compounding pharmacies
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters The roughly $1,000 monthly price tag of Eli Lilly‘s weight loss drug Zepbound put the blockbuster treatment out of reach for Willow Baillies, 29, whose insurance does not cover it. Baillies,…
-
Danaher had a disappointing 2024. Its path to success subsequent 12 months goes by means of Wall Road
Life sciences firm Danaher has certainly not been an easy stock to own this year. A wave of startups going public on Wall Street would go a long ways toward changing that. Year-to-date performance: down 0.1% Forward price-to-earnings multiple: 27.8 versus a five-year average of 28.8 Our rating: Buy-equivalent 1 Our price target: $305 a…
-
FDA approves Eli Lilly’s weight reduction drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Shelby Knowles | Bloomberg | Getty Images The Food and Drug Administration on Friday approved Eli Lilly‘s blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, expanding…
-
Ozempic faces scrutiny over potential eye situation threat
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. There may be a…
-
UnitedHealth Group CEO Andrew Witty addresses Brian Thompson demise
Andrew Witty, CEO of UnitedHealth Group, testifies during the Senate Finance Committee hearing titled “Hacking America’s Health Care: Assessing the Change Healthcare Cyber Attack and What’s Next,” in the Dirksen Building in Washington, D.C., on May 1, 2024. Tom Williams | Cq-roll Call, Inc. | Getty Images UnitedHealth Group CEO Andrew Witty on Friday mourned…
-
Weight-loss drug increase has grow to be one of many web’s largest scams
A production line of Wegovy injection pens for the Asian market at the Novo Nordisk A/S pharmaceutical manufacturing facility in Hillerod, Denmark, on Wednesday, Nov. 27, 2024. Bloomberg | Bloomberg | Getty Images One interpretation of the law of supply and demand is that when demand outstrips supply, scammers get busy. That’s certainly the case…
-
CDC says McDonald’s E. coli outbreak is over
In this photo illustration, a McDonald’s Quarter Pounder hamburger meal is seen at a McDonald’s on October 23, 2024 in the Flatbush neighborhood in the Brooklyn borough of New York City. Michael M. Santiago | Getty Images The Centers for Disease Control and Prevention on Tuesday said the deadly E. coli outbreak linked to slivered…
